This Is Your Government on Conservatism

WASHINGTON - U.S. health officials evaluated the wrong factory when assessing the safety of a Chinese-made drug ingredient that may be a source of problems with a blood thinner, the Food and Drug Administration said Monday.

Baxter International's heparin has been linked to four deaths and hundreds of reports of allergic reactions. An investigation will take FDA inspectors to China this week.

The Chinese manufacturer was not inspected because it was confused with another company in the agency's database with a similar name, said Joseph Famulare, deputy director of the Center for Drug Evaluation and Research's compliance department. The FDA evaluated that firm, which had a history of positive inspections and was not re-inspected.

More, if you can stand it.

Views expressed on this page are those of the authors and not necessarily those of Campaign for America's Future or Institute for America's Future